GlaxoSmithKline in $1.5 billion collaboration deal

Share this article:
GlaxoSmithKline announced a deal on Thursday with the privately held drug research firm ChemoCentryx to discover, develop and market novel medicines for a variety of inflammatory disorders. As part of the deal ChemoCentryx will receive an upfront payment of $63.5 million and will be eligible to earn milestone payments up to, potentially, $1.5 billion. Under the agreement, Mountain View, CA-based ChemoCentryx will also get a double digit royalty percentage on collaboration product sales, and an investment from GlaxoSmithKline should the company go public. ChemoCentryx's Traficet-EN, which is in late stage development for the treatment of inflammatory bowel disease, is included in the agreement.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.